Overexpression of GATA1 Confers Resistance to Chemotherapy in Acute Megakaryocytic Leukemia

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Caldwell, John Timothy ^a   Edwards, Holly ^a   Dombkowski, Alan A ^a,b   Buck, Steven A ^a,b   Matherly, Larry H ^a   Ge, Yubin ^a   Taub, Jeffrey W ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; PROTEIN BCL XL; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR GATA 1; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BCL X GENE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEGAKARYOBLAST; MEGAKARYOCYTE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; GATA1 TRANSCRIPTION FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MICROARRAY ANALYSIS; UP-REGULATION; VALPROIC ACID;

ARA;

EID: 84880031922     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068601     Document Type: Article

References (44)

1. Gassmann W, Löffler H, (1995) Acute Megakaryoblastic Leukemia. Leuk Lymphoma 18: 69-73. doi:10.3109/10428199509064924. PubMed: 7496359.
2. Ribeiro RC, Oliveira MSP, Fairclough D, Hurwitz C, Mirro J, et al. (1993) Acute Megakaryoblastic Leukemia in Children and Adolescents: A Retrospective Analysis of 24 Cases. Leuk Lymphoma 10: 299-306. doi:10.3109/10428199309148552. PubMed: 8220128.
3. Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, et al. (2001) Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood 97: 3727-3732. doi:10.1182/blood.V97.12.3727. PubMed: 11389009.
4. O'Brien MM, Cao X, Pounds S, Dahl GV, Raimondi SC, et al. (2012) Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG. p. 9421. Leukemia.
5. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, et al. (1992) Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 80: 2210-2214. PubMed: 1384797.
6. Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, et al. (1998) Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 91: 608-615. PubMed: 9427716.
7. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, et al. (2003) Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol 21: 3415-3422. doi:10.1200/JCO.2003.08.060. PubMed: 12885836.
8. Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J, (1994) Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res 18: 163-171. doi:10.1016/0145-2126(94)90111-2. PubMed: 8139285.
9. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, et al. (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32: 148-152. doi:10.1038/ng955. PubMed: 12172547.
10. Crispino JD, (2005) GATA1 in normal and malignant hematopoiesis. Semin in Cell & Amp; Dev Biol 16: 137-147. PubMed: 15659348.
11. Ross ME, Mahfouz R, Onciu M, Liu H-C, Zhou X, et al. (2004) Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104: 3679-3687. doi:10.1182/blood-2004-03-1154. PubMed: 15226186.
12. Ayala RM, Martínez-López J, Albízua E, Diez A, Gilsanz F, (2009) Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia. Am J Hematol 84: 79-86. doi:10.1002/ajh.21332. PubMed: 19097174.
13. Shimamoto T, Ohyashiki K, Ohyashiki JH, Kawakubo K, Fujimura T, et al. (1995) The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia. Blood 86: 3173-3180. PubMed: 7579412.
14. Opferman JT, (2007) Life and death during hematopoietic differentiation. Curr Opin Immunol 19: 497-502. doi:10.1016/j.coi.2007.06.002. PubMed: 17662585.
15. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, et al. (1995) Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 267: 1506-1510. doi:10.1126/science.7878471. PubMed: 7878471.
16. Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, et al. (1999) GATA-1 and Erythropoietin Cooperate to Promote Erythroid Cell Survival by Regulating bcl-xL Expression. Blood 94: 87-96. PubMed: 10381501.
17. Kuo YY, Chang ZF, (2007) GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcription. Mol Cell Biol 27: 4261-4272. doi:10.1128/MCB.02212-06. PubMed: 17420275.
18. Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, et al. (1999) Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 94: 1393-1400. PubMed: 10438727.
19. Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, et al. (2005) GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst 97: 226-231. doi:10.1093/jnci/dji026. PubMed: 15687366.
20. Mogal A, Abdulkadir SA, (2006) Effects of Histone Deacetylase Inhibitor (HDACi); Trichostatin-A (TSA) on the expression of housekeeping genes. Mol Cell Probes 20: 81-86. doi:10.1016/j.mcp.2005.09.008. PubMed: 16326072.
21. Xie C, Edwards H, Xu X, Zhou H, Buck SA, et al. (2010) Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia. Clin Cancer Res 16: 5499-5510. doi:10.1158/1078-0432.CCR-10-1707. PubMed: 20889917.
22. Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, et al. (2009) RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 114: 2744-2752. doi:10.1182/blood-2008-09-179812. PubMed: 19638627.
23. Ge Y, Jensen TL, Matherly LH, Taub JW, (2003) Transcriptional regulation of the cystathionine-β-synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. Blood 101: 1551-1557. doi:10.1182/blood-2002-07-2337. PubMed: 12393509.
24. Ge Y, LaFiura KM, Dombkowski AA, Chen Q, Payton SG, et al. (2007) The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia 22: 521-529. PubMed: 18094719.
25. Rajagopalan D, (2003) A comparison of statistical methods for analysis of high density oligonucleotide array data. Bioinformatics 19: 1469-1476. doi:10.1093/bioinformatics/btg202. PubMed: 12912826.
26. Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, et al. (2006) Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 107: 1570-1581. doi:10.1182/blood-2005-06-2219. PubMed: 16249385.
27. Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, et al. (2004) The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 64: 728-735. doi:10.1158/0008-5472.CAN-03-2456. PubMed: 14744791.
28. Chateauvieux S, Eifes S, Morceau F, Grigorakaki C, Schnekenburger M, et al. (2011) Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway. Biochem Pharmacol 81: 498-509. doi:10.1016/j.bcp.2010.11.011. PubMed: 21108933.
29. Huang da W, Sherman BT, Lempicki RA, (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13. doi:10.1093/nar/gkn923. PubMed: 19033363.
30. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57. PubMed: 19131956.
31. Kodama T, Hikita H, Kawaguchi T, Shigekawa M, Shimizu S, et al. (2012) Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death Differ 19: 1856-1869. doi:10.1038/cdd.2012.88. PubMed: 22790873.
32. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, et al. (2009) Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113: 299-305. PubMed: 18931344.
33. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, et al. (2008) A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies. Clin Cancer Res 14: 8295-8301. doi:10.1158/1078-0432.CCR-08-0999. PubMed: 19088047.
34. Xu X, Xie C, Edwards H, Zhou H, Buck SA, et al. (2011) Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells. PLOS ONE 6: e17138. doi:10.1371/journal.pone.0017138. PubMed: 21359182.
35. Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, et al. (2012) Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest 122: 948-962. doi:10.1172/JCI60455. PubMed: 22354171.
36. Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, et al. (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 15: 1161-1164. doi:10.1038/sj.leu.2402174. PubMed: 11480556.
37. Lonigro L, Mirabile E, Munda S, Barchitta M, Bottino D, et al. (2008) Association between high expression of natural killer related-genes (NCAM/CD94) and early death during induction in children with acute myeloid leukemia. Leukemia 22: 1778-1781. doi:10.1038/leu.2008.46. PubMed: 18323797.
38. Guo B, Liu Y, Tan X, Cen H, (2012) Prognostic significance of vascular endothelial growth factor expression in adult patients with acute myeloid leukemia: a meta-analysis. Leuk: Lymphoma.
39. Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, et al. (2010) Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 116: 1539-1547. doi:10.1182/blood-2009-06-230474. PubMed: 20472832.
40. Vázquez I, Maicas M, Cervera J, Agirre X, Marin-Béjar O, et al. (2011) Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica 96: 1448-1456. doi:10.3324/haematol.2011.040535. PubMed: 21750091.
41. Kanda Y, Hamaki T, Yamamoto R, Chizuka A, Suguro M, et al. (2000) The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer 88: 2529-2533. doi:10.1002/1097-0142(20000601)88:11. PubMed: 10861429.
42. Zhu HH, Liu YR, Jiang H, Lu J, Qin YZ, et al. (2013) CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation. Leuk: Res.
43. Pfirrmann M, Ehninger G, Thiede C, Bornhäuser M, Kramer M, et al. (2012) Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol 13: 207-214. doi:10.1016/S1470-2045(11)70326-6. PubMed: 22197676.
44. Quintás-Cardama A, Santos FP, Garcia-Manero G, (2011) Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25: 226-235. doi:10.1038/leu.2010.276. PubMed: 21116282.